Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,437

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It

Breijyeh, Zeinab, Jubeh, Buthaina, Karaman, Rafik·2020·Molecules
DOI 10.3390/molecules25061340PMC PMC7144564
Open this paper in CoChat — free account

Abstract

Antimicrobial resistance represents an enormous global health crisis and one of the most serious threats humans face today. Some bacterial strains have acquired resistance to nearly all antibiotics. Therefore, new antibacterial agents are crucially needed to overcome resistant bacteria. In 2017, the World Health Organization (WHO) has published a list of antibiotic-resistant priority pathogens, pathogens which present a great threat to humans and to which new antibiotics are urgently needed the list is categorized according to the urgency of need for new antibiotics as critical, high, and medium priority, in order to guide and promote research and development of new antibiotics. The majority of the WHO list is Gram-negative bacterial pathogens. Due to their distinctive structure, Gram-negative bacteria are more resistant than Gram-positive bacteria, and cause significant morbidity and mortality worldwide. Several strategies have been reported to fight and control resistant Gram-negative bacteria, like the development of antimicrobial auxiliary agents, structural modification of existing antibiotics, and research into and the study of chemical structures with new mechanisms of action and novel targets that resistant bacteria are sensitive to. Research efforts have been made to meet the urgent need for new treatments; some have succeeded to yield activity against resistant Gram-negative bacteria by deactivating the mechanism of resistance, like the action of the β-lactamase Inhibitor antibiotic adjuvants. Another promising trend was by referring to nature to develop naturally derived agents with antibacterial activity on novel targets, agents such as bacteriophages, DCAP(2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2(hydroxymethyl)propane1,3-diol, Odilorhabdins (ODLs), peptidic benzimidazoles, quorum sensing (QS) inhibitors, and metal-based antibacterial agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules25061340

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 WHO list of priority pathogens grouped under three priority categories according to their antibiotic resistance: Critical, high and medium to encourage research and development of new antibiotics.
Figure 1 WHO list of priority pathogens grouped under three priority categories according to their antibiotic resistance: Critical, high and medium to encourage research and development of new antibiotics.CC BY · PubMed Central
Figure 2 A diagram describes the cell wall structure of Gram-negative bacteria.
Figure 2 A diagram describes the cell wall structure of Gram-negative bacteria.CC BY · PubMed Central
Figure 3 Structure of Gram-negative bacteria and their mechanisms of resistance.
Figure 3 Structure of Gram-negative bacteria and their mechanisms of resistance.CC BY · PubMed Central
Figure 4 Chemical structures of clavulanic acid, salbactam, tazobactam, LN-1-255, DBOs core, relebactam, zidebactam, RPX7009, DCAP, peptidic benzimidazol, isobutyl-DPD and phenyl-DPD.
Figure 4 Chemical structures of clavulanic acid, salbactam, tazobactam, LN-1-255, DBOs core, relebactam, zidebactam, RPX7009, DCAP, peptidic benzimidazol, isobutyl-DPD and phenyl-DPD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 116

  1. Coico, 2006, Gram staining, Curr. Protoc. Microbiol., 1, A.3C.1
  2. Moyes, 2009, Differential Staining of Bacteria: Gram Stain, Curr. Protoc. Microbiol., 15, 3
  3. Silhavy, 2010, The Bacterial Cell Envelope, Cold Spring Harb. Perspect. Boil., 2, a000414
  4. Murray, P.R., Rosenthal, K.S., and Pfaller, M.A. (2005). Medical Microbiology, Elsevier.
  5. Miller, 2016, Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules, mBio, 7, e01541-16, 10.1128/mBio.01541-16 · DOI
  6. Datta, 2019, Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids, Indian J. Med. Res., 149, 97, 10.4103/ijmr.IJMR_755_18 · DOI
  7. Woerther, 2015, Mechanisms of antimicrobial resistance in Gram-negative bacilli, Ann. Intensiv. Care, 5, 61
  8. Paterson, 2006, Resistance in gram-negative bacteria: Enterobacteriaceae, Am. J. Med., 34, S20, 10.1016/j.amjmed.2006.03.013 · DOI
  9. 2017, Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know, Virulence, 8, 379, 10.1080/21505594.2017.1306621 · DOI
  10. Lutgring, 2019, Carbapenem-resistant Enterobacteriaceae: An emerging bacterial threat, Semin. Diagn. Pathol., 36, 182, 10.1053/j.semdp.2019.04.011 · DOI
  11. Lee, 2017, Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options, Front. Microbiol., 7, 55
  12. Lin, 2014, Antimicrobial resistance inAcinetobacter baumannii: From bench to bedside, World J. Clin. Cases, 2, 787, 10.12998/wjcc.v2.i12.787 · DOI
  13. Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Gene Funct. Dis., 6, 109, 10.1016/j.gendis.2019.04.001 · DOI
  14. Savoldi, 2018, Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions, Gastroenterology, 155, 1372, 10.1053/j.gastro.2018.07.007 · DOI
  15. Park, 2016, Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA, Dig. Dis. Sci., 61, 2373, 10.1007/s10620-016-4091-8 · DOI
  16. Alba, 2017, Antibiotic resistance in Helicobacter pylori, Curr. Opin. Infect. Dis., 30, 489, 10.1097/QCO.0000000000000396 · DOI
  17. Smith, 2010, Fluoroquinolone Resistance in Campylobacter, J. Food Prot., 73, 1141, 10.4315/0362-028X-73.6.1141 · DOI
  18. Sproston, E.L., Wimalarathna, H.M.L., and Sheppard, S.K. (2018). Trends in fluoroquinolone resistance in Campylobacter. Microb. Genom., 4. · DOI
  19. Cuypers, W., Jacobs, J., Wong, V., Klemm, E.J., Deborggraeve, S., and Van Puyvelde, S. (2018). Fluoroquinolone resistance in Salmonella: Insights by whole-genome sequencing. Microb. Genom., 4. · DOI
  20. Parry, 2015, Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections, Clin. Microbiol. Rev., 28, 901, 10.1128/CMR.00002-15 · DOI
  21. Masters, 2016, Gonorrhea - an evolving disease of the new millennium, Microb. Cell, 3, 371, 10.15698/mic2016.09.524 · DOI
  22. Bala, 2010, Cephalosporin Resistance in Neisseria gonorrhoeae, J. Glob. Infect. Dis., 2, 284, 10.4103/0974-777X.68537 · DOI
  23. Barry, 2009, The use of cephalosporins for gonorrhea: The impending problem of resistance, Expert Opin. Pharmacother., 10, 555, 10.1517/14656560902731993 · DOI
  24. Ghanem, 2005, Fluoroquinolone-resistant Neisseria gonorrhoeae: The Inevitable Epidemic, Infect. Dis. Clin. North Am., 19, 351, 10.1016/j.idc.2005.03.005 · DOI
  25. Moreira, 2017, Antimicrobial resistance in Neisseria gonorrhoeae: History, molecular mechanisms and epidemiological aspects of an emerging global threat, Braz. J. Microbiol., 48, 617, 10.1016/j.bjm.2017.06.001 · DOI
  26. Heinz, 2018, The return of Pfeiffer’s bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae, Microb. Genom., 4, e000214
  27. Tristram, 2007, Antimicrobial Resistance in Haemophilus influenzae, Clin. Microbiol. Rev., 20, 368, 10.1128/CMR.00040-06 · DOI
  28. Bae, 2009, Antimicrobial Resistance in Haemophilus influenzae Respiratory Tract Isolates in Korea: Results of a Nationwide Acute Respiratory Infections Surveillance▿, Antimicrob. Agents Chemother., 54, 65, 10.1128/AAC.00966-09 · DOI
  29. Qin, 2017, Newest data on fluoroquinolone resistance mechanism of Shigella flexneri isolates in Jiangsu Province of China, Antimicrob. Resist. Infect. Control., 6, 97, 10.1186/s13756-017-0249-1 · DOI
  30. Heini, 2016, Shigella Antimicrobial Drug Resistance Mechanisms, 2004–2014, Emerg. Infect. Dis., 22, 1083, 10.3201/eid2206.152088 · DOI
  31. Xu, 2019, Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections, Bioorganic Med. Chem., 27, 3209, 10.1016/j.bmc.2019.06.017 · DOI
  32. Bernal, 2013, Antibiotic adjuvants: Identification and clinical use, Microb. Biotechnol., 6, 445, 10.1111/1751-7915.12044 · DOI
  33. Gill, 2014, Antibiotic Adjuvants: Diverse Strategies for Controlling Drug-Resistant Pathogens, Chem. Boil. Drug Des., 85, 56, 10.1111/cbdd.12478 · DOI
  34. Walsh, 2000, Molecular mechanisms that confer antibacterial drug resistance, Nature, 406, 775, 10.1038/35021219 · DOI
  35. 2017, Antibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics, Bioorganic Med. Chem. Lett., 27, 4221, 10.1016/j.bmcl.2017.08.027 · DOI
  36. Drawz, 2013, New β-Lactamase Inhibitors: A Therapeutic Renaissance in an MDR World, Antimicrob. Agents Chemother., 58, 1835, 10.1128/AAC.00826-13 · DOI
  37. Leonard, 2013, Class D β-Lactamases: A Reappraisal after Five Decades, Accounts Chem. Res., 46, 2407, 10.1021/ar300327a · DOI
  38. Klingler, 2015, Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria, J. Med. Chem., 58, 3626, 10.1021/jm501844d · DOI
  39. Reading, 1977, Clavulanic Acid: A Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus, Antimicrob. Agents Chemother., 11, 852, 10.1128/AAC.11.5.852 · DOI
  40. Buynak, 1999, The synthesis and evaluation of 6-alkylidene-2′β-substituted penam sulfones as β-lactamase inhibitors, Bioorganic Med. Chem. Lett., 9, 1997, 10.1016/S0960-894X(99)00325-X · DOI
  41. Vallejo, 2016, LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48, J. Antimicrob. Chemother., 71, 2171, 10.1093/jac/dkw105 · DOI
  42. Mangoni, A.A., Guillou, C., Vanden Eynde, J.J., Hulme, C., Jampilek, J., Li, W., Prokai-Tatrai, K., Rautio, J., Collina, S., and Tuccinardi, T. (2018). Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes (-)4. Molecules, 2. · DOI
  43. Coleman, 2011, Diazabicyclooctanes (DBOs): A potent new class of non-β-lactam β-lactamase inhibitors, Curr. Opin. Microbiol., 14, 550, 10.1016/j.mib.2011.07.026 · DOI
  44. Walkty, 2014, Ceftazidime–avibactam: An evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections, Core Évid., 9, 13
  45. Maneiro, 2017, Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii, Antimicrob. Agents Chemother., 61, e01172-17, 10.1128/AAC.01172-17 · DOI
  46. Leone, 2019, New antimicrobial options for the management of complicated intra-abdominal infections, Eur. J. Clin. Microbiol. Infect. Dis., 38, 819, 10.1007/s10096-019-03533-y · DOI
  47. Wright, 2017, New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?, Clin. Microbiol. Infect., 23, 704, 10.1016/j.cmi.2017.09.001 · DOI
  48. Sader, 2017, WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015, Antimicrob. Agents Chemother., 61, e00072-17, 10.1128/AAC.00072-17 · DOI
  49. Smoum, 2012, Boron Containing Compounds as Protease Inhibitors, Chem. Rev., 112, 4156, 10.1021/cr608202m · DOI
  50. Beesley, 1983, The inhibition of class C β-lactamases by boronic acids, Biochem. J., 209, 229, 10.1042/bj2090229 · DOI
  51. Hecker, 2015, Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases, J. Med. Chem., 58, 3682, 10.1021/acs.jmedchem.5b00127 · DOI
  52. Goldstein, 2013, In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria, Antimicrob. Agents Chemother., 57, 2620, 10.1128/AAC.02418-12 · DOI
  53. 1917, Sur un microbe invisible antagoniste des bacilles dysentériques, CR Acad. Sci. Paris, 165, 373
  54. Chanishvili, N., and Aminov, R.I. (2019). Bacteriophage therapy: Coping with the growing antibiotic resistance problem. Microbiol. Aust. · DOI
  55. Kortright, 2019, Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria, Cell Host Microbe, 25, 219, 10.1016/j.chom.2019.01.014 · DOI
  56. McCallin, 2013, Safety analysis of a Russian phage cocktail: From MetaGenomic analysis to oral application in healthy human subjects, Virology, 443, 187, 10.1016/j.virol.2013.05.022 · DOI
  57. Borysowski, 2012, Clinical Aspects of Phage Therapy, Advances in Clinical Chemistry, 83, 73
  58. Wright, 2009, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistantPseudomonas aeruginosa; a preliminary report of efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI
  59. Sultana, 2016, Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh, EBioMedicine, 4, 124, 10.1016/j.ebiom.2015.12.023 · DOI
  60. Jault, 2019, Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial, Lancet Infect. Dis., 19, 35, 10.1016/S1473-3099(18)30482-1 · DOI
  61. Oechslin, 2017, Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence, J. Infect. Dis., 215, 703
  62. Huff, 2004, Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers, Poult. Sci., 83, 1944, 10.1093/ps/83.12.1944 · DOI
  63. Ye, 2019, Bacteriophages as Environmental Reservoirs of Antibiotic Resistance, Trends Microbiol., 27, 570, 10.1016/j.tim.2019.02.008 · DOI
  64. Thanbichler, 2006, MipZ, a Spatial Regulator Coordinating Chromosome Segregation with Cell Division in Caulobacter, Cell, 126, 147, 10.1016/j.cell.2006.05.038 · DOI
  65. Eun, 2012, DCAP: A Broad-Spectrum Antibiotic That Targets the Cytoplasmic Membrane of Bacteria, J. Am. Chem. Soc., 134, 11322, 10.1021/ja302542j · DOI
  66. Heinrich, 2015, DCAP: A broad-spectrum antibiotic that targets the cytoplasmic membrane of bacteria, FASEB J., 29, 575.6, 10.1096/fasebj.29.1_supplement.575.6 · DOI
  67. Hurley, 2015, Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria, ACS Med. Chem. Lett., 6, 466, 10.1021/acsmedchemlett.5b00024 · DOI
  68. Polikanov, 2018, The Mechanisms of Action of Ribosome-Targeting Peptide Antibiotics, Front. Mol. Biosci., 5, 48, 10.3389/fmolb.2018.00048 · DOI
  69. 2005, Bioactive Microbial Metabolites, J. Antibiot., 58, 1, 10.1038/ja.2005.1 · DOI · Paper page
  70. Pantel, 2018, Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site, Mol. Cell, 70, 83, 10.1016/j.molcel.2018.03.001 · DOI
  71. Bansal, 2012, The therapeutic journey of benzimidazoles: A review, Bioorganic Med. Chem., 20, 6208, 10.1016/j.bmc.2012.09.013 · DOI · Paper page
  72. Boiani, 2005, Imidazole and benzimidazole derivatives as chemotherapeutic agents, Mini-Reviews Med. Chem., 5, 409, 10.2174/1389557053544047 · DOI
  73. Jain, 2005, Bacterial Peptide deformylase inhibitors: A new class of antibacterial agents, Curr. Med. Chem., 12, 1607, 10.2174/0929867054367194 · DOI
  74. Becker, 1998, Structure of Peptide Deformylase and Identification of the Substrate Binding Site, J. Boil. Chem., 273, 11413, 10.1074/jbc.273.19.11413 · DOI
  75. Nguyen, 2003, Characterization of a Human Peptide Deformylase: Implications for Antibacterial Drug Design†, Biochemistry, 42, 9952, 10.1021/bi0346446 · DOI
  76. Bird, 2018, Expedient on-resin synthesis of peptidic benzimidazoles, Bioorganic Med. Chem. Lett., 28, 2679, 10.1016/j.bmcl.2018.04.062 · DOI
  77. Bugday, 2017, Synthesis and Evaluation of Novel Benzimidazole Conjugates Incorporating Amino Acids and Dipeptide Moieties, Lett. Org. Chem., 14, 198, 10.2174/1570178614666170203093406 · DOI
  78. Stotani, S., Gatta, V., Medda, F., Padmanaban, M., Karawajczyk, A., Tammela, P., Giordanetto, F., Tzalis, D., and Collina, S. (2018). A Versatile Strategy for the Synthesis of 4,5-Dihydroxy-2,3-Pentanedione (DPD) and Related Compounds as Potential Modulators of Bacterial Quorum Sensing. Molecules, 23. · DOI
  79. Stotani, 2019, DPD-Inspired Discovery of Novel LsrK Kinase Inhibitors: An Opportunity To Fight Antimicrobial Resistance, J. Med. Chem., 62, 2720, 10.1021/acs.jmedchem.9b00025 · DOI
  80. Gasser, 2015, Metal Complexes and Medicine: A Successful Combination, Chim. Int. J. Chem., 69, 442, 10.2533/chimia.2015.442 · DOI
  81. Medici, 2016, Silver coordination compounds: A new horizon in medicine, Co-ord. Chem. Rev., 327, 349, 10.1016/j.ccr.2016.05.015 · DOI
  82. Lovering, 2009, Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success, J. Med. Chem., 52, 6752, 10.1021/jm901241e · DOI
  83. Hung, 2011, Route to three-dimensional fragments using diversity-oriented synthesis, Proc. Natl. Acad. Sci., 108, 6799, 10.1073/pnas.1015271108 · DOI
  84. Li, 2015, Ruthenium complexes as antimicrobial agents, Chem. Soc. Rev., 44, 2529, 10.1039/C4CS00343H · DOI
  85. Smitten, 2019, Using Nanoscopy To Probe the Biological Activity of Antimicrobial Leads That Display Potent Activity against Pathogenic, Multidrug Resistant, Gram-Negative Bacteria, ACS Nano, 13, 5133, 10.1021/acsnano.8b08440 · DOI
  86. Abebe, 2016, Synthesis and Assessment of Antibacterial Activities of Ruthenium(III) Mixed Ligand Complexes Containing 1,10-Phenanthroline and Guanide, Bioinorg. Chem. Appl., 2016, 1, 10.1155/2016/3607924 · DOI
  87. Bonchi, 2014, Repurposing of gallium-based drugs for antibacterial therapy, BioFactors, 40, 303, 10.1002/biof.1159 · DOI
  88. Wang, 2019, Combination of gallium(iii) with acetate for combating antibiotic resistant Pseudomonas aeruginosa, Chem. Sci., 10, 6099, 10.1039/C9SC01480B · DOI
  89. Fock, 2013, Helicobacter pylori research: Historical insights and future directions, Nat. Rev. Gastroenterol. Hepatol., 10, 495, 10.1038/nrgastro.2013.96 · DOI
  90. Li, 2018, Systems Approaches for Unveiling the Mechanism of Action of Bismuth Drugs: New Medicinal Applications beyond Helicobacter Pylori Infection, Accounts Chem. Res., 52, 216, 10.1021/acs.accounts.8b00439 · DOI
  91. Wang, 2018, Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors, Nat. Commun., 9, 439, 10.1038/s41467-018-02828-6 · DOI
  92. Luqman, 2014, Homo- and Heteroleptic Bismuth(III/V) Thiolates from N-Heterocyclic Thiones: Synthesis, Structure and Anti-Microbial Activity, Chem. A Eur. J., 20, 14362, 10.1002/chem.201404109 · DOI
  93. Luqman, 2016, The Importance of Heterolepticity in Improving the Antibacterial Activity of Bismuth(III) Thiolates, Eur. J. Inorg. Chem., 2016, 2738, 10.1002/ejic.201600076 · DOI
  94. Werrett, 2018, Bismuth Phosphinates in Bi-Nanocellulose Composites and their Efficacy towards Multi-Drug Resistant Bacteria, Chem. A Eur. J., 24, 12938, 10.1002/chem.201801803 · DOI
  95. Muller, 2016, Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains, Clin. Res. Hepatol. Gastroenterol., 40, 517, 10.1016/j.clinre.2015.12.012 · DOI
  96. Alexander, 2009, History of the Medical Use of Silver, Surg. Infect., 10, 289, 10.1089/sur.2008.9941 · DOI
  97. Aziz, 2012, A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds, Burns, 38, 307, 10.1016/j.burns.2011.09.020 · DOI
  98. Sierra, 2019, Bio-Organometallic Derivatives of Antibacterial Drugs, Chem. A Eur. J., 25, 7232, 10.1002/chem.201805985 · DOI
  99. Yan, 2016, Antibacterial activity of silver nanoparticles synthesized In-situ by solution spraying onto cellulose, Carbohydr. Polym., 147, 500, 10.1016/j.carbpol.2016.03.029 · DOI
  100. Mijnendonckx, 2013, Antimicrobial silver: Uses, toxicity and potential for resistance, BioMetals, 26, 609, 10.1007/s10534-013-9645-z · DOI
  101. Frei, A. (2020). Metal Complexes, an Untapped Source of Antibiotic Potential?. Antibiotics, 9. · DOI
  102. Ma, 2017, Antibacterial evaluation of sliver nanoparticles synthesized by polysaccharides from Astragalus membranaceus roots, Biomed. Pharmacother., 89, 351, 10.1016/j.biopha.2017.02.009 · DOI
  103. Kareem, 2017, Combination effect of edible mushroom–sliver nanoparticles and antibiotics against selected multidrug biofilm pathogens, Iraq Med. J., 1, 68
  104. Kareem, A. (2018). Combination Effect of Edible Mushroom – Sliver Nanoparticles and Antibioticsagainst selected Multidrug Biofilm Pathogens. Int. J. Res. Pharm. Sci., 9. · DOI
  105. Rai, 2012, Silver nanoparticles: The powerful nanoweapon against multidrug-resistant bacteria, J. Appl. Microbiol., 112, 841, 10.1111/j.1365-2672.2012.05253.x · DOI
  106. Panzner, 2007, N-Heterocyclic carbene–silver complexes: A new class of antibiotics, Co-ord. Chem. Rev., 251, 884, 10.1016/j.ccr.2006.08.019 · DOI
  107. Johnson, N.A., Southerland, M.R., and Youngs, W.J. (2017). Recent Developments in the Medicinal Applications of Silver-NHC Complexes and Imidazolium Salts. Molecules, 22. · DOI
  108. Vincent, 2016, Antimicrobial applications of copper, Int. J. Hyg. Environ. Heal., 219, 585, 10.1016/j.ijheh.2016.06.003 · DOI
  109. Vincent, 2018, Contact killing and antimicrobial properties of copper, J. Appl. Microbiol., 124, 1032, 10.1111/jam.13681 · DOI
  110. Dalecki, 2017, Copper and Antibiotics, Adv. Microb. Physiol., 70, 193, 10.1016/bs.ampbs.2017.01.007 · DOI
  111. Bondarczuk, 2013, Molecular basis of active copper resistance mechanisms in Gram-negative bacteria, Cell Boil. Toxicol., 29, 397, 10.1007/s10565-013-9262-1 · DOI
  112. Djoko, 2015, Copper(II)-Bis(Thiosemicarbazonato) Complexes as Antibacterial Agents: Insights into Their Mode of Action and Potential as Therapeutics, Antimicrob. Agents Chemother., 59, 6444, 10.1128/AAC.01289-15 · DOI
  113. Perdih, 2012, Different types of copper complexes with the quinolone antimicrobial drugs ofloxacin and norfloxacin: Structure, DNA- and albumin-binding, J. Inorg. Biochem., 117, 35, 10.1016/j.jinorgbio.2012.08.008 · DOI
  114. Thummeepak, R., Pooalai, R., Harrison, C., Gannon, L., Thanwisai, A., Chantratita, N., Millard, A., and Sitthisak, S. (2020). Essential Gene Clusters Involved in Copper Tolerance Identified in Acinetobacter baumannii Clinical and Environmental Isolates. Pathogens, 9. · DOI
  115. Lee, 2015, Educational Effectiveness, Target, and Content for Prudent Antibiotic Use, BioMed Res. Int., 2015, 1
  116. Alink, 2015, Patient information leaflets to reduce antibiotic use and reconsultation rates in general practice: A systematic review, BMJ Open, 5, 007612

Cited by

See all 1,437

Metadata

Authors
Breijyeh, Z., Jubeh, B., & Karaman, R.
Venue
Molecules
Publisher
MDPI AG
Published
2020-03-16
Volume
25
Issue
6
Pages
1340
ISSN
1420-3049
DOI
10.3390/molecules25061340
PMC
PMC7144564
Cited by
1,437
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. https://app.cochat.ai/papers/10.3390/molecules25061340
The paper
Breijyeh, Z., Jubeh, B., & Karaman, R. (2020). Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules. https://doi.org/10.3390/molecules25061340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.